Ferrous Sulfate Versus Lactoferrin in Treatment of Pregnant Females with Iron Deficiency Anemia | ||
| Benha Journal of Applied Sciences | ||
| Article 23, Volume 7, Issue 11, November 2022, Pages 135-138 PDF (361.41 K) | ||
| Document Type: Original Research Papers | ||
| DOI: 10.21608/bjas.2022.293879 | ||
| Authors | ||
| M.M. Mahmoud1; M.A. Abdelfatah2; A.W. Anwar2; A.A. Elfalah3 | ||
| 1Gynecology and Obstetric, Kafr Shukr Central Hospital, Qalyubia, Egypt. | ||
| 2Gynecology and Obstetric, Dept., Faculty of Medicine, Benha Univ., Benha, Egypt | ||
| 3Clinical Pathology, Dept., Faculty of Medicine, Benha Univ., Benha, Egypt | ||
| Abstract | ||
| Iron preparations, of which ferrous sulphate is the most common, are utilised in a broad variety of industries across the globe. This medicine has a high risk of adverse effects, most of which are related to the digestive system, despite being effective and inexpensive. As a transferrin family member and glycoprotein, lactoferrin is one of the proteins that can bind to and transport iron. The purpose of this research was to examine the haematological response and potential adverse effects of oral ferrous sulphate and oral lactoferrin as iron supplements for the treatment of iron deficiency anaemia (IDA) in pregnant women. A total of 108 pregnant women with a diagnosis of IDA were included in this research; 54 participants from each group. Iron sulphate (Ferro sanol duodenal cap, MINAPHARM Company) and lactoferrin (Pravotin, HYGINT Company) were both given orally to one group, while the other was given lactoferrin. Both treatments lasted for 4 weeks. Pregnancy-related or preexisting maternal diseases (such as hypertension, gestational diabetes, thyroid dysfunctions, pituitary diseases, nutritional diseases, liver pathologies, and gastrointestinal disorders), foetal abnormalities (such as microcephaly, intrauterine growth restriction), and allergy to any of the given drugs (iron sulphate [Ferro sanol duodenal cap, MINAPHARM Com]; or any of the other given drugs) disqualified subjects (Pravotin, HYGINT Company). Before and after treatment, both groups were compared for differences in outcomes and side effects, such as [haemoglobin (Hb) level, serum iron, ferritin level, total iron binding capacity (TIBC)]. No significant changes were seen in baseline or post-treatment Hb level, iron, TIBC, or ferritin levels between the two groups. As an added bonus, group A had much more nausea than group B. The incidence of vomiting was much greater in group A than in group B. Group A had considerably more cases of abdominal discomfort than Group B. People in Group A had more constipation than those in Group B. The current research concludes that oral lactoferrin has less adverse effects than oral iron therapy for the treatment of IDA during pregnancy. | ||
| Keywords | ||
| Ferrous sulfate; hemoglobin; iron deficiency anemia; lactoferrin; total binding capacity | ||
|
Statistics Article View: 203 PDF Download: 334 |
||
